US Patent 9,011,906: Claim Scope, Qsymia Exclusivity, Patent Landscape and Generic Entry Risk
US Patent 9,011,906 protects specific weight-loss treatment regimens using controlled-release topiramate and immediate-release phentermine, the active ingredients in Qsymia. Its principal protection is not the broad concept of combining the two drugs. The claims focus on dose escalation, defined strengths, controlled-release pharmacokinetics, obesity-related patient populations and treatment outcomes.
The patent is assigned to Vivus, Inc., the developer of Qsymia. It issued April 21, 2015, and belongs to the Qsymia patent family. Its nominal family term runs into 2027, subject to the official USPTO patent-term calculation, terminal disclaimers and any applicable adjustment.[1]
What does US Patent 9,011,906 protect?
The patent protects methods of treating overweight or obese patients with an escalating oral dosage regimen consisting of:
| Regimen stage |
Controlled-release topiramate |
Immediate-release phentermine |
Equivalent phentermine hydrochloride |
| Initial dose |
23 mg |
3.75 mg |
Approximately 4.92 mg |
| Intermediate dose |
46 mg |
7.5 mg |
Approximately 9.84 mg |
| Higher dose |
92 mg |
15 mg |
Not expressly recited in the supplied claims |
Claims 1 through 16 cover an initial 23 mg/3.75 mg regimen followed by a 46 mg/7.5 mg regimen. Claims 17 through 31 cover an initial 23 mg/3.75 mg regimen followed by a 92 mg/15 mg regimen.
The claims require controlled-release topiramate to reach maximum plasma concentration approximately six to 10 hours after administration. Several dependent claims also require a lower peak concentration than immediate-release or non-controlled-release topiramate while maintaining total exposure, measured by area under the concentration-time curve.
This pharmacokinetic limitation distinguishes the claimed product from a simple coadministration of ordinary topiramate and phentermine.
How are the claims organized?
Independent claim architecture
The two main independent claims are claims 1 and 17.
Claim 1 requires:
- A patient with a body mass index of at least 25 kg/m2.
- A first dosage form containing 23 mg controlled-release topiramate and 3.75 mg immediate-release phentermine.
- Daily administration of the first dosage form for at least two weeks.
- A second dosage form containing 46 mg controlled-release topiramate and 7.5 mg immediate-release phentermine.
- A controlled-release topiramate Tmax of approximately six to 10 hours.
Claim 17 has the same structure but substitutes 92 mg topiramate and 15 mg phentermine for the second dosage form.
The claims therefore cover two principal Qsymia escalation paths:
- 23 mg/3.75 mg followed by 46 mg/7.5 mg.
- 23 mg/3.75 mg followed by 92 mg/15 mg.
The approved Qsymia label includes these strengths and also includes a 69 mg/11.25 mg intermediate strength used before the highest dose.[2] The supplied claims do not expressly recite the 69 mg/11.25 mg dosage form.
Dependent claim groups
Claims 2 through 9 and 18 through 25 narrow the patient population by BMI and comorbidity.
Claims 10, 13, 14, 26, 28 and 29 narrow the formulation and pharmacokinetic characteristics.
Claims 11, 12 and 27 address the conversion between phentermine base and phentermine hydrochloride.
Claims 15 and 30 require oral administration.
Claims 16 and 31 require weight loss of at least approximately 10% of body weight.
What are the strongest limitations in US Patent 9,011,906?
The strongest limitations are the combination of dose, dosage-form design and pharmacokinetics. A competing product or generic would need to evaluate each limitation independently.
Dose and sequence
A product that uses 23 mg/3.75 mg as an initial dose and then 46 mg/7.5 mg or 92 mg/15 mg is exposed to the core claim structure. The requirement that the first dosage form be administered daily for at least two weeks creates a temporal limitation that may be important in infringement analysis.
The claim language does not expressly state how soon the second dosage form must follow the first. That omission may create claim-construction issues. The ordinary clinical use of Qsymia supplies a likely sequence, but a court would analyze the text, specification and prosecution history.
Controlled-release topiramate
The controlled-release requirement is central. A formulation containing immediate-release topiramate would not literally satisfy this limitation, although the patent holder could evaluate equivalents depending on the formulation’s release profile and prosecution history.
Claim 14 and claim 29 expressly include sustained release, delayed release, or both. The claims therefore reach more than one controlled-release mechanism.
Pharmacokinetic profile
The six-to-10-hour Tmax requirement is a measurable product characteristic. Claims 10, 13, 26 and 28 add a lower Cmax than non-controlled-release topiramate without reducing AUC.
This limitation creates both protection and vulnerability:
- It strengthens the claims by tying them to a defined pharmacokinetic result.
- It creates an evidentiary burden involving clinical or bioanalytical testing.
- It may permit a design-around using a release profile with a materially different Tmax or Cmax.
- It raises questions about the reference formulation used for comparison.
The term “about” provides numerical flexibility, but the scope depends on the specification, experimental data and accepted analytical variation.
Patient population
The independent claims apply to patients with BMI of at least 25 kg/m2, covering both overweight patients and obese patients. Dependent claims separately recite BMI of 25 to 29.9 kg/m2 and BMI of at least 30 kg/m2.
The comorbidity claims are narrower. They cover conditions such as hypertension, dyslipidemia, type 2 diabetes mellitus, elevated fasting blood glucose and high triglycerides. The broader lists in claims 5 and 21 include cardiovascular, metabolic, respiratory, reproductive and cancer-related conditions.
How does US Patent 9,011,906 compare with the Qsymia product?
Qsymia is an extended-release capsule containing phentermine hydrochloride and topiramate. FDA approved Qsymia in July 2012 for chronic weight management in adults with an initial BMI of at least 30 kg/m2, or at least 27 kg/m2 with at least one weight-related comorbidity.[2]
The patent claims use a BMI threshold of 25 kg/m2. That is broader than the principal FDA-labeled BMI threshold for Qsymia. The patent consequently covers some patients who fall outside the original labeled population, although product liability and induced-infringement analysis would depend on the approved labeling and actual use.
| Issue |
US 9,011,906 |
Qsymia label |
| Active ingredients |
Topiramate and phentermine |
Topiramate and phentermine |
| Topiramate release |
Controlled release |
Extended release |
| Phentermine release |
Immediate release |
Immediate release component |
| Initial strength |
23 mg/3.75 mg |
23 mg/3.75 mg |
| Subsequent claimed strength |
46 mg/7.5 mg or 92 mg/15 mg |
46/7.5, 69/11.25 and 92/15 mg |
| BMI threshold in claims |
At least 25 kg/m2 |
At least 30, or at least 27 with a comorbidity |
| Initial treatment period |
At least two weeks |
Label-directed titration |
| PK limitation |
Tmax about six to 10 hours |
Extended-release product profile |
The overlap with Qsymia is direct. The patent was drafted around the product’s formulation and dose-escalation characteristics rather than around the chemical identity of either active ingredient.
What other patents protect Qsymia?
Qsymia’s patent estate includes formulation, composition, pharmacokinetic and treatment-method patents. Public FDA Orange Book records have identified multiple Vivus patents associated with Qsymia, including US 8,557,797, US 8,895,557 and US 9,011,906.[3]
The relevant patent categories are:
| Patent category |
Protected subject matter |
Generic exposure |
| Combination composition |
Phentermine plus controlled-release topiramate |
High if the ANDA uses the same combination |
| Controlled-release formulation |
Release technology and dosage-form architecture |
High for matching extended-release capsules |
| Dose escalation |
Initial and maintenance dose schedules |
High if the proposed label copies the Qsymia regimen |
| Pharmacokinetics |
Tmax, Cmax and AUC relationships |
Depends on comparative testing |
| Method of treatment |
BMI, obesity and comorbidity populations |
Depends on label language and induced use |
| Manufacturing |
Drug-layering, release-control and capsule processes |
Depends on the generic manufacturing process |
The patent landscape must be assessed as a portfolio rather than by reviewing US 9,011,906 alone. A generic may avoid one claim set and still face other Orange Book-listed patents or non-listed manufacturing patents.
What is the Orange Book status of US 9,011,906?
US 9,011,906 has been associated with Qsymia in FDA Orange Book patent listings. Orange Book listing creates a statutory reference point for ANDA applicants and can trigger the Hatch-Waxman Paragraph IV process.[3]
An applicant seeking approval of a generic version of Qsymia must address each listed patent through one of four certifications:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the patent has expired.
- Paragraph III: approval is sought after patent expiration.
- Paragraph IV: the patent is invalid, unenforceable or will not be infringed.
For US 9,011,906, a Paragraph IV certification would likely require analysis of:
- Whether the proposed product contains the claimed strengths.
- Whether topiramate is controlled release.
- Whether the product satisfies the claimed Tmax range.
- Whether the proposed labeling instructs the claimed escalation schedule.
- Whether the proposed label covers the BMI and comorbidity populations.
- Whether any claim is invalid for anticipation, obviousness, written-description failure or indefiniteness.
When does US Patent 9,011,906 lose exclusivity?
The Qsymia patent family has a nominal expiration period in 2027 based on its underlying family term. The precise enforceable date must be taken from the USPTO patent record and FDA Orange Book because patent-term adjustment, terminal disclaimers and regulatory extensions can affect the operative date.[1,3]
FDA approval exclusivity is separate from patent exclusivity. Qsymia received new-drug approval in 2012. Its five-year new chemical entity exclusivity would have expired before US 9,011,906 issued. The commercial barrier therefore depends principally on patent rights, not remaining FDA NCE exclusivity.
A generic could obtain approval before patent expiration through a successful Paragraph IV pathway, a litigation settlement permitting earlier launch or a finding that the relevant patents do not block approval.
Which companies have challenged Qsymia patents?
The principal commercial challenge to Qsymia has involved generic-drug applicants seeking approval for phentermine/topiramate products. Vivus has used Hatch-Waxman litigation and settlement arrangements to protect the product’s commercial period.
Publicly reported Qsymia patent disputes have involved Actavis and other generic applicants. Settlement terms have reportedly contemplated a permitted generic entry date in December 2025, subject to the applicable agreement and patent rights.[4]
A settlement date is not the same as a patent expiration date. It may reflect a negotiated license, a covenant not to sue or a commercial compromise. The operative agreement controls the permitted launch conditions.
What Paragraph IV risks exist for a Qsymia generic?
Infringement risks
A conventional Qsymia generic would face substantial risk under the core claims if it uses:
- 23 mg/3.75 mg as the starting strength.
- At least two weeks of initial treatment.
- 46 mg/7.5 mg or 92 mg/15 mg as a subsequent strength.
- Controlled-release topiramate.
- Immediate-release phentermine.
- An extended-release profile with a six-to-10-hour topiramate Tmax.
- Labeling that instructs the patented treatment regimen.
A Paragraph IV applicant may argue that its formulation does not meet the Tmax or Cmax limitations. That defense would require reliable comparative testing and a consistent definition of the reference product.
Induced infringement
Method claims create label-based exposure. If a proposed generic label instructs physicians to use the product according to the patented dose-escalation regimen, Vivus could assert induced infringement under 35 U.S.C. § 271(b).
A “skinny label” strategy could remove patented indications or dosing instructions. Its effectiveness would depend on whether the remaining label still encourages the claimed use and whether the patented regimen is central to ordinary use of the product.
Invalidity risks
Potential invalidity arguments include:
- Obviousness based on earlier phentermine/topiramate combination studies.
- Anticipation by prior clinical protocols or formulations.
- Indefiniteness involving “about,” “controlled release,” “escalating unit dosage form” or PK comparisons.
- Written-description issues for the broad condition lists.
- Lack of enablement across the full range of release technologies and patient populations.
The formulation and pharmacokinetic limitations may make anticipation more difficult if the prior art does not disclose the claimed release profile. Obviousness remains a more credible challenge because dose escalation, extended release and obesity treatment were known technical concepts before the patent’s filing date.
How strong is the patent estate for Qsymia?
The estate is commercially meaningful because it combines multiple enforcement theories:
- Product-based claims can target the formulation.
- Method claims can target the approved dosing regimen.
- PK claims can reach formulations that use different physical designs but produce the same exposure profile.
- Orange Book listings can trigger automatic approval stays after Paragraph IV litigation.
- Continuation patents can extend prosecution and preserve overlapping claim coverage.
Its principal weakness is claim specificity. The more precisely a claim defines Tmax, Cmax, dose sequence and BMI, the more opportunities a generic has to demonstrate non-infringement through formulation or labeling changes.
The estate is strongest against a conventional generic that seeks to copy Qsymia’s dosage forms, strengths, pharmacokinetic profile and titration instructions. It is weaker against a product using different strengths, a different release profile or a materially different label.
What formulations are protected by US 9,011,906?
The patent protects dosage forms with:
- Controlled-release or sustained-release topiramate.
- Immediate-release phentermine.
- Oral administration.
- A specified combination of active-ingredient amounts.
- A topiramate Tmax of approximately six to 10 hours.
- In certain dependent claims, lower Cmax without reduced AUC.
The claims do not require a particular excipient, coating, capsule shell, manufacturing process or release-control polymer in the supplied text. Those details may be disclosed in the specification or protected by related patents, but they are not express limitations of claims 1 and 17.
This distinction matters in freedom-to-operate analysis. A formulation can avoid a specific excipient patent while still infringing US 9,011,906 if it satisfies the claimed product and PK limitations.
What manufacturing and geographic barriers apply?
US 9,011,906 is a US patent. Its direct infringement provisions apply to manufacture, use, sale, offer for sale and importation in the United States. Foreign manufacture can create US exposure if the patented product is imported into the United States.
A generic manufacturer also must address:
- FDA ANDA requirements.
- Bioequivalence for the combination product.
- Controlled-substance handling requirements for phentermine.
- Topiramate formulation reproducibility.
- Comparative PK testing.
- Manufacturing-process patents that may not be fully disclosed by the product claims.
- Patent rights in Europe, Canada and other jurisdictions where equivalent family members may exist.
A US design-around does not establish freedom to operate in other countries. Geographic analysis requires a separate family-by-family review of prosecution, maintenance and national-phase status.
Key Takeaways
- US 9,011,906 protects Qsymia-type dose escalation using controlled-release topiramate and immediate-release phentermine.
- Claims 1 and 17 are the principal claim sets.
- The protected sequences are 23 mg/3.75 mg followed by 46 mg/7.5 mg or 92 mg/15 mg.
- The six-to-10-hour topiramate Tmax is a central limitation.
- Dependent claims add lower Cmax, preserved AUC, BMI thresholds, obesity-related conditions, oral administration and at least 10% weight loss.
- The patent overlaps directly with FDA-approved Qsymia dosing and formulation characteristics.
- Qsymia’s broader patent estate includes formulation and related combination patents, including US 8,557,797 and US 8,895,557.
- The family’s nominal patent protection extends into 2027, while reported settlement arrangements have contemplated generic entry in December 2025.
- The largest generic risks arise from copying the Qsymia label, strengths, titration schedule and extended-release PK profile.
- The most credible design-around strategies involve changing the release profile, dose sequence, strengths or label instructions.
FAQs About US Patent 9,011,906
Does US 9,011,906 cover phentermine or topiramate alone?
No. The supplied claims require a combination of topiramate and phentermine. They do not cover either active ingredient administered alone.
Does the patent cover the 69 mg/11.25 mg Qsymia strength?
The supplied claims do not expressly recite the 69 mg/11.25 mg strength. Other Qsymia patents or claim sets may cover that strength or the broader product regimen.
Can a generic avoid infringement by using immediate-release topiramate?
Potentially, because controlled-release topiramate is a core limitation. The generic would still need to assess related patents and whether its formulation performs an equivalent function in substantially the same way.
Does FDA approval automatically infringe the patent?
No. FDA approval and patent infringement are separate issues. A generic may receive approval subject to patent certification, litigation outcomes, settlement restrictions or a delayed commercial launch.
Is a 2025 generic launch guaranteed by the Qsymia settlement?
No. A settlement may establish contractual launch rights, but commercial entry also depends on regulatory approval, manufacturing readiness, supply arrangements and any continuing patent or litigation restrictions.
References
-
United States Patent and Trademark Office. (2015). US Patent No. 9,011,906, methods for treating obesity using controlled release topiramate and phentermine. https://patents.google.com/patent/US9011906B2/en
-
U.S. Food and Drug Administration. (2023). Qsymia prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Reuters. (2016). Vivus settles patent litigation over Qsymia with Actavis. Reuters pharmaceutical litigation reporting.
